deferoxamine has been researched along with Cochlear Hearing Loss in 29 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the incidence of sensory neural hearing loss (SNHL) in beta-thalassemia major patients treated with deferoxamine in Mofid Children's Hospital." | 7.74 | Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine. ( Alavi, S; Aminasnafi, A; Amini, R; Arzanian, MT; Esfehani, H; Gachkar, L; Garallahi, F; Moghadassian, H; Shamsian, BS, 2008) |
| "This study evaluated the incidence of sensory neural hearing loss (SNHL) in beta-thalassemia major patients treated with deferoxamine in Mofid Children's Hospital." | 3.74 | Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine. ( Alavi, S; Aminasnafi, A; Amini, R; Arzanian, MT; Esfehani, H; Gachkar, L; Garallahi, F; Moghadassian, H; Shamsian, BS, 2008) |
| "Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia, 13 presented with visual loss or deafness of acute onset or both." | 3.67 | Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. ( Buncic, JR; Chew, E; Gallant, T; Harrison, RV; Keenan, N; Logan, W; Mitchell, D; Olivieri, NF; Ricci, G; Skarf, B, 1986) |
| "Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia." | 1.33 | Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. ( Chen, LJ; Chen, SH; Cheng, SY; Liang, DC; Lin, HC; Liu, HC, 2005) |
| " Thus we suggest periodical audiologic checkups and a low dosage of DFO (below 50 mg/kg/day) given on at least 5-6 days a week for the prevention and prompt diagnosis of audiologic complications." | 1.31 | Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. ( Asadi-Pooya, AA; Asadi-Pooya, K; Karimi, M; Khademi, B; Yarmohammadi, H, 2002) |
| "All patients with beta -thalassemia major received daily chelation therapy with subcutaneous injection of desferrioxamine (30-50 mgkg(-1)per day)." | 1.31 | Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. ( Ambrosetti, U; Cappellini, MD; Dondè, E; Piatti, G, 2000) |
| " Unfortunately it presents some toxic effects." | 1.29 | [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results]. ( Greco Miani, A; Meleleo, D; Parlatore, L; Sacco, M; Serra, E; Tricarico, N, 1994) |
| " In this paper we studied the eventually adverse otologic effects of DFO in 20 patients receiving haemodialysis." | 1.28 | [Ototoxicity of deferoxamine]. ( Biurrun, O; de España, R; Lorente, J; Orteu, N; Traserra, J; Valls, J, 1992) |
| " Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible." | 1.28 | Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. ( Cases, A; Griño, MC; Kelly, J; Lopez-Pedret, J; Revert, L; Sabater, F; Torras, A, 1990) |
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| "Forty-seven patients with thalassaemia have been studied to define risk factors for development of sensorineural hearing loss, and to establish guidelines for safe chelation." | 1.28 | Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. ( East, CA; Hazell, JW; Huehns, ER; Jaswon, MS; Porter, JB, 1989) |
| "Among our patients, conductive hearing loss was not more frequent than in patients without beta thalassemia." | 1.27 | Hearing loss and desferrioxamine in homozygous beta-thalassemia. ( Albera, R; Bianco, L; Gabutti, V; Lacilla, M; Morra, B; Pia, F; Piga, A, 1988) |
| "When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic." | 1.27 | Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. ( Boyden, MH; Carley, H; Freedman, MH; Gallant, LA; Gallant, T, 1987) |
| " However, the desferrioxamine dosage was similar in both our groups (less than 60 mg/kg a day), and lower in the affected group than other authors have reported." | 1.27 | Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major. ( Barratt, PS; Toogood, IR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (37.93) | 18.7374 |
| 1990's | 10 (34.48) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanphaichitr, A | 1 |
| Kusuwan, T | 1 |
| Limviriyakul, S | 1 |
| Atipas, S | 1 |
| Pooliam, J | 1 |
| Sangpraypan, T | 1 |
| Tanphaichitr, VS | 1 |
| Viprakasit, V | 1 |
| Osma, U | 1 |
| Kurtoglu, E | 1 |
| Eyigor, H | 1 |
| Yilmaz, MD | 1 |
| Aygener, N | 1 |
| Shamsian, BS | 1 |
| Aminasnafi, A | 1 |
| Moghadassian, H | 1 |
| Gachkar, L | 1 |
| Arzanian, MT | 1 |
| Alavi, S | 1 |
| Esfehani, H | 1 |
| Garallahi, F | 1 |
| Amini, R | 1 |
| Karimi, M | 1 |
| Asadi-Pooya, AA | 1 |
| Khademi, B | 1 |
| Asadi-Pooya, K | 1 |
| Yarmohammadi, H | 1 |
| Kontzoglou, G | 2 |
| Koussi, A | 2 |
| Economou, M | 1 |
| Tsatra, I | 1 |
| Perifanis, V | 1 |
| Noussios, G | 2 |
| Athanassiou-Metaxa, M | 1 |
| Chen, SH | 1 |
| Liang, DC | 1 |
| Lin, HC | 1 |
| Cheng, SY | 1 |
| Chen, LJ | 1 |
| Liu, HC | 1 |
| Sacco, M | 1 |
| Meleleo, D | 1 |
| Tricarico, N | 1 |
| Greco Miani, A | 1 |
| Serra, E | 1 |
| Parlatore, L | 1 |
| Boelaert, JR | 1 |
| de Locht, M | 1 |
| Tsatra, J | 1 |
| Vital, V | 1 |
| Sagarakis, G | 1 |
| Athanassiou, M | 1 |
| Porter, JB | 2 |
| Faherty, A | 1 |
| Stallibrass, L | 1 |
| Brookman, L | 1 |
| Hassan, I | 1 |
| Howes, C | 1 |
| Yamanobe, S | 1 |
| Kanno, H | 1 |
| Ambrosetti, U | 1 |
| Dondè, E | 1 |
| Piatti, G | 1 |
| Cappellini, MD | 1 |
| Pinna, A | 1 |
| Corda, L | 1 |
| Carta, F | 1 |
| de España, R | 1 |
| Biurrun, O | 1 |
| Lorente, J | 1 |
| Valls, J | 1 |
| Orteu, N | 1 |
| Traserra, J | 1 |
| Triantafyllou, N | 1 |
| Fisfis, M | 1 |
| Sideris, G | 1 |
| Triantafyllou, D | 1 |
| Rombos, A | 1 |
| Vrettou, H | 1 |
| Mantouvalos, V | 1 |
| Politi, C | 1 |
| Malliara, S | 1 |
| Papageorgiou, C | 1 |
| Argiolu, F | 1 |
| Diana, G | 1 |
| Avignone, A | 1 |
| Cao, A | 1 |
| Di Ninni, S | 1 |
| Cases, A | 2 |
| Kelly, J | 2 |
| Sabater, F | 1 |
| Torras, A | 2 |
| Griño, MC | 1 |
| Lopez-Pedret, J | 1 |
| Revert, L | 2 |
| Cohen, A | 1 |
| Martin, M | 1 |
| Mizanin, J | 1 |
| Konkle, DF | 1 |
| Schwartz, E | 1 |
| Caballero, LG | 1 |
| Günther, T | 1 |
| Rebentisch, E | 1 |
| Vormann, J | 1 |
| Jaswon, MS | 1 |
| Huehns, ER | 1 |
| East, CA | 1 |
| Hazell, JW | 1 |
| Albera, R | 1 |
| Pia, F | 1 |
| Morra, B | 1 |
| Lacilla, M | 1 |
| Bianco, L | 1 |
| Gabutti, V | 1 |
| Piga, A | 1 |
| Masala, W | 1 |
| Meloni, F | 1 |
| Gallisai, D | 1 |
| Careddu, M | 1 |
| Secchi, G | 1 |
| Cuccuru, GB | 1 |
| Loriga, V | 1 |
| Salvo, G | 1 |
| Sabater, J | 1 |
| Campistol, JM | 1 |
| Montoliu, J | 1 |
| López, I | 1 |
| Schindléry, C | 1 |
| Olivieri, NF | 1 |
| Buncic, JR | 1 |
| Chew, E | 1 |
| Gallant, T | 2 |
| Harrison, RV | 1 |
| Keenan, N | 1 |
| Logan, W | 1 |
| Mitchell, D | 1 |
| Ricci, G | 1 |
| Skarf, B | 1 |
| Boyden, MH | 1 |
| Gallant, LA | 1 |
| Carley, H | 1 |
| Freedman, MH | 1 |
| Barratt, PS | 1 |
| Toogood, IR | 1 |
| Orton, RB | 1 |
| de Veber, LL | 1 |
| Sulh, HM | 1 |
1 review available for deferoxamine and Cochlear Hearing Loss
| Article | Year |
|---|---|
[Auditory, visual and neurologic toxicity of deferoxamine].
Topics: Adolescent; Cataract; Deferoxamine; Hearing Loss, Sensorineural; Humans; Male; Middle Aged | 1989 |
28 other studies available for deferoxamine and Cochlear Hearing Loss
| Article | Year |
|---|---|
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; | 2014 |
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cros | 2015 |
Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Topics: Adolescent; Audiometry, Pure-Tone; beta-Thalassemia; Cross-Sectional Studies; Deferoxamine; Female; | 2008 |
Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Deferoxamine; Dose-Response Relations | 2002 |
Long term audiological evaluation of beta-thalassemic patients.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; beta-Thalassemia; Child; Deferoxamine; Evoked Potentials, | 2004 |
Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Anemia, Hemolytic, Congenital; beta-Thalassemia; Chelat | 2005 |
[Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
Topics: Adolescent; Adult; Audiometry; beta-Thalassemia; Deferoxamine; Dose-Response Relationship, Drug; Fem | 1994 |
Side-effects of desferrioxamine in dialysis patients.
Topics: Bacterial Infections; Brain Diseases; Deferoxamine; Eye; Hearing Loss, Sensorineural; Humans; Iron; | 1993 |
Sensorineural hearing loss in children with thalassemia major in Northern Greece.
Topics: Acoustic Impedance Tests; Adolescent; Adult; Antidotes; Audiometry; beta-Thalassemia; Child; Deferox | 1996 |
A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
Topics: Adolescent; Adult; Audiometry; beta-Thalassemia; Deferoxamine; Electroretinography; Female; Hearing | 1998 |
[An experimental study of ototoxicity induced by deferoxamine mesilate].
Topics: Action Potentials; Animals; Chelating Agents; Cochlea; Deferoxamine; Female; Guinea Pigs; Hair Cells | 1998 |
Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
Topics: Adolescent; Adult; Audiology; beta-Thalassemia; Chelating Agents; Deferoxamine; Female; Hearing Loss | 2000 |
Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
Topics: Administration, Oral; Adult; Astringents; Chelating Agents; Deferoxamine; Female; Hearing Loss, Sens | 2001 |
[Ototoxicity of deferoxamine].
Topics: Adult; Audiometry; Audiometry, Pure-Tone; Deferoxamine; Evoked Potentials, Auditory, Brain Stem; Fem | 1992 |
Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
Topics: Adult; Audiometry, Pure-Tone; Auditory Threshold; Blood Transfusion; Brain Stem; Deferoxamine; Elect | 1991 |
Hearing impairment during deferoxamine therapy for thalassemia major.
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1991 |
Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
Topics: Adult; Aged; Aged, 80 and over; Aluminum; Chelation Therapy; Deferoxamine; Female; Hearing Loss, Bil | 1990 |
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Protection against salicylate ototoxicity by zinc.
Topics: Animals; Deferoxamine; Female; Hearing Loss, Sensorineural; Injections, Subcutaneous; Magnesium; Mal | 1989 |
Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Drug Evaluation; Female; Ferritins; Hearin | 1989 |
Hearing loss and desferrioxamine in homozygous beta-thalassemia.
Topics: Adolescent; Audiometry; Child; Deferoxamine; Female; Hearing Loss, Conductive; Hearing Loss, Sensori | 1988 |
Can deferoxamine be considered an ototoxic drug?
Topics: Adolescent; Adult; Child; Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1988 |
Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine.
Topics: Acute Disease; Adult; Aged; Deferoxamine; Female; Hearing Loss; Hearing Loss, Bilateral; Hearing Los | 1988 |
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Topics: Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1988 |
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Audiometry; Child; Child, Preschool; Color Vision | 1986 |
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
Topics: Adolescent; Adult; Audiometry; Child; Child, Preschool; Deferoxamine; Hearing Loss; Hearing Loss, Hi | 1987 |
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Child; Deferoxamine; Drug Administration Schedule; Hearing Loss, Sensorineural; H | 1987 |
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
Topics: Child, Preschool; Deferoxamine; Ear; Eye; Female; Hearing Loss, Sensorineural; Humans; Injections, S | 1985 |